Stefano Campaner

Researcher

Research Lines

Genomic Science

Center

cgs-semm

Contacts

Center for Genomic Science of IIT@SEMM Fondazione Istituto Italiano di Tecnologia (IIT) at the IFOM-IEO Campus Via Adamello 16

About

 

NAME

Stefano Campaner

POSITION TITLE

 Team Leader

 

EDUCATION/TRAINING 

INSTITUTION AND LOCATION

DEGREE

YEAR(s)

FIELD OF STUDY

 

 

 

 

University of Milan, Italy

Degree

    1992 

Biology

Department of General Physiology and Biochemistry, University of Milan, Italy

PhD

1993-1997

Biochemistry

Genetics Branch, National Cancer Institute, NIH (USA)

Post-doc

1998-2003

Cell cycle-Tumor biology

European Institute of Oncology, Milan, Italy

Post-doc

2003-2010

Cell cycle-Tumor biology

European Institute of Oncology, Milan, Italy

Staff-Scientist

2010-2011

Cell cycle-Tumor biology

IIT@SEMM, Center for Genomic Science,  Fondazione Istituto Italiano di Tecnologia (IIT)

Team Leader

2012

Cell cycle-Tumor biology

         

 

Positions and Employment

1993-1997:    PhD student in Biochemistry, at the Department of General Physiology and Biochemistry,University of Milan, Italy .

1998-2003:    Post-doctoral fellow, National Cancer Institute, National Institute of Health, USA

2003-2009:    Post-doctoral fellow , European Institute of Oncology, Milan, Italy

2009-2012:    Professor of Molecular and Cellular Oncology, University of Milano-Bicocca, Italy

2009-2011:    Staff Scientist, European Institute of Oncology, Milan, Italy

2012:            Team leader,  Cancer Biology, Center for Genomic Science of IIT@SEMM, Milan Italy

 

Honors

Recipient of the 2002 Fellow Award for Research Excellence at NIH

Fogarty post-doctoral fellowship award, from January 1998 to June 2003

Keystone Symposia scholarship funded by the International Society of Differentiation (July-2008)

 

Patents

PHARMACEUTICAL COMPOSITION AND METHOD FOR REGULATING ABNORMAL CELLULAR PROLIFERATION  PCT Patent Application No. PCT IL2006-001324.

Selected Publications

1. Campaner S, Amati B. Two sides of the Myc-induced DNA damage response. from
tumor suppression to tumor maintenance. Cell Div. 2012 Feb 28;7(1).6.

2. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF,
D'Artista L, Schleker T, Guerra C, Garcia E, Barbacid M, Hidalgo M, Amati B,
Fernandez-Capetillo O. Exploiting oncogene-induced replicative stress for the
selective killing of Myc-driven tumors. Nat Struct Mol Biol. 2011 Nov
27;18(12).1331-5.

3. Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, Testa G. The
methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage
response in vivo. Mol Cell. 2011 Aug 19;43(4).681-8.

4. Miluzio A, Beugnet A, Grosso S, Brina D, Mancino M, Campaner S, Amati B, de
Marco A, Biffo S. Impairment of cytoplasmic eIF6 activity restricts
lymphomagenesis and tumor progression without affecting normal growth. Cancer
Cell. 2011 Jun 14;19(6).765-75.

5. Campaner S, Doni M, Verrecchia A, Faga’ G, Bianchi L, Amati B. Myc, Cdk2 and
cellular senescence. Old players, new game. Cell Cycle. 2010 Sep
15;9(18).3655-61.

6. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, Schleker
T, Perna D, Tronnersjö S, Murga M, Fernandez-Capetillo O, Barbacid M, Larsson LG,
Amati B. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat
Cell Biol. 2010 Jan;12(1).54-9; sup pp 1-14.

7. Magnifico A, Albano L, Campaner S, Delia D, Castiglioni F, Gasparini P, Sozzi
G, Fontanella E, Menard S, Tagliabue E. Tumor-initiating cells of HER2-positive
carcinoma cell lines express the highest oncoprotein levels and are sensitive to
trastuzumab. Clin Cancer Res. 2009 Mar 15;15(6).2010-21.

8. Magnifico A, Albano L, Campaner S, Campiglio M, Pilotti S, Menard S, Tagliabue
E. Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2
protein overexpression without gene amplification. Cancer Res. 2007 Jun
1;67(11).5308-17.

9. Erez A, Castiel A, Trakhtenbrot L, Perelman M, Rosenthal E, Goldstein I,
Stettner N, Harmelin A, Eldar-Finkelman H, Campaner S, Kirsch I, Izraeli S. The
SIL gene is essential for mitotic entry and survival of cancer cells. Cancer Res.
2007 May 1;67(9).4022-7. Epub 2007 Apr 24. Erratum in. Cancer Res. 2007 Jun
15;67(12).5998.

10. Campaner S, Kaldis P, Izraeli S, Kirsch IR. Sil phosphorylation in a Pin1
binding domain affects the duration of the spindle checkpoint. Mol Cell Biol.
2005 Aug;25(15).6660-72.

11. Erez A, Perelman M, Hewitt SM, Cojacaru G, Goldberg I, Shahar I, Yaron P,
Muler I, Campaner S, Amariglio N, Rechavi G, Kirsch IR, Krupsky M, Kaminski N,
Izraeli S. Sil overexpression in lung cancer characterizes tumors with increased
mitotic activity. Oncogene. 2004 Jul 8;23(31).5371-7.

12. Izraeli S, Lowe LA, Bertness VL, Campaner S, Hahn H, Kirsch IR, Kuehn MR.
Genetic evidence that Sil is required for the Sonic Hedgehog response pathway.
Genesis. 2001 Oct;31(2).72-7.

13. Molla G, Porrini D, Job V, Motteran L, Vegezzi C, Campaner S, Pilone MS,
Pollegioni L. Role of arginine 285 in the active site of Rhodotorula gracilis
D-amino acid oxidase. A site-directed mutagenesis study. J Biol Chem. 2000 Aug
11;275(32).24715-21.

14. Campaner S, Pollegioni L, Ross BD, Pilone MS. Limited proteolysis and
site-directed mutagenesis reveal the origin of microheterogeneity in Rhodotorula
gracilis D-amino acid oxidase. Biochem J. 1998 Mar 1;330 ( Pt 2).615-21.

15. Pollegioni L, Molla G, Campaner S, Martegani E, Pilone MS. Cloning,
sequencing and expression in E. coli of a D-amino acid oxidase cDNA from
Rhodotorula gracilis active on cephalosporin C. J Biotechnol. 1997 Oct
17;58(2).115-23.

16. Pollegioni L, Campaner S, Raibekas AA, Pilone MS. Identification of a
reactive cysteine in the flavin-binding domain of Rhodotorula gracilis D-amino
acid oxidase. Arch Biochem Biophys. 1997 Jul 1;343(1).1-5..

17. Pollegioni L, Campaner S, Raibekas AA, Pilone MS. Reactivity of sulfhydryl
groups of Rhodotorula gracilis D-amino acid oxidase. Biochem Soc Trans. 1996
Feb;24(1).21S.